CL2025000145A1 - Soluciones farmacéuticas de anticuerpos anti-n3pglu aß y usos de estas - Google Patents

Soluciones farmacéuticas de anticuerpos anti-n3pglu aß y usos de estas

Info

Publication number
CL2025000145A1
CL2025000145A1 CL2025000145A CL2025000145A CL2025000145A1 CL 2025000145 A1 CL2025000145 A1 CL 2025000145A1 CL 2025000145 A CL2025000145 A CL 2025000145A CL 2025000145 A CL2025000145 A CL 2025000145A CL 2025000145 A1 CL2025000145 A1 CL 2025000145A1
Authority
CL
Chile
Prior art keywords
n3pglu
antibodies
pharmaceutical solutions
pharmaceutical
solutions
Prior art date
Application number
CL2025000145A
Other languages
English (en)
Spanish (es)
Inventor
John Corvari Vincent
H Durbin Nicole
Navanithan Sharma Anant
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2025000145A1 publication Critical patent/CL2025000145A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CL2025000145A 2022-07-21 2025-01-16 Soluciones farmacéuticas de anticuerpos anti-n3pglu aß y usos de estas CL2025000145A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263369033P 2022-07-21 2022-07-21

Publications (1)

Publication Number Publication Date
CL2025000145A1 true CL2025000145A1 (es) 2025-05-30

Family

ID=87576063

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025000145A CL2025000145A1 (es) 2022-07-21 2025-01-16 Soluciones farmacéuticas de anticuerpos anti-n3pglu aß y usos de estas

Country Status (18)

Country Link
EP (1) EP4558166A1 (fr)
JP (1) JP2025525587A (fr)
KR (1) KR20250037554A (fr)
CN (1) CN119604302A (fr)
AR (1) AR129994A1 (fr)
AU (1) AU2023309007A1 (fr)
CA (1) CA3261418A1 (fr)
CL (1) CL2025000145A1 (fr)
CO (1) CO2025000508A2 (fr)
CR (1) CR20250023A (fr)
DO (1) DOP2025000005A (fr)
IL (1) IL318102A (fr)
JO (1) JOP20250013A1 (fr)
MA (1) MA71558A (fr)
MX (1) MX2025000820A (fr)
PE (1) PE20250785A1 (fr)
TW (1) TW202421188A (fr)
WO (1) WO2024020470A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3042917T3 (pl) * 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie

Also Published As

Publication number Publication date
PE20250785A1 (es) 2025-03-14
DOP2025000005A (es) 2025-02-28
CO2025000508A2 (es) 2025-02-04
WO2024020470A1 (fr) 2024-01-25
JP2025525587A (ja) 2025-08-05
JOP20250013A1 (ar) 2025-01-21
CA3261418A1 (fr) 2024-01-25
AU2023309007A1 (en) 2025-01-30
CR20250023A (es) 2025-02-17
AR129994A1 (es) 2024-10-23
CN119604302A (zh) 2025-03-11
MA71558A (fr) 2025-05-30
TW202421188A (zh) 2024-06-01
MX2025000820A (es) 2025-03-07
IL318102A (en) 2025-02-01
KR20250037554A (ko) 2025-03-17
EP4558166A1 (fr) 2025-05-28

Similar Documents

Publication Publication Date Title
CL2021003290A1 (es) Anticuerpos de unión a cd3. (divisional de solicitud 201900643)
BRPI0410684A (pt) uso de um peptìdio conjugado a uma proteìna que age como um imunógeno para a produção de anticorpos capazes de reconhecer especificamente qualquer uma das variantes predominantes do peptìdeo beta amilóide aß40 e aß42 na preparação de um medicamento para a prevenção e/ou o tratamento de uma doença e uso de um anticorpo ou um fragmento ativo ou o derivado de um anticorpo que reconhece especificamente qualquer uma das variantes predominantes do peptìdio beta amilóide, aß40 e aß42, na preparação de um medicamento para prevenção e/ou tratamento de uma doença
JOP20190155B1 (ar) مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
AR029619A1 (es) Vacuna
BR112018075222A2 (pt) anticorpos anti-tnfrsf25
AR115721A1 (es) Anticuerpos que comprenden un polipéptido insertado en la región marco 3
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
MX2021013491A (es) Nuevas endolisinas de gardnerella y usos de las mismas.
CL2023000853A1 (es) Compuestos y composiciones como moduladores de señalización tlr
BR112018067946A2 (pt) formulações tópicas contendo ciclosporina e usos das mesmas
AR121118A1 (es) Factores de transcripción de proteínas de dedos de zinc para reprimir la expresión de tau
UY33258A (es) Proteinas de union a antigeno
EP4566629A3 (fr) Utilisation d'un échange de plasma à faible volume pour le traitement de la maladie d'alzheimer dans des stades précoces et intermédiaires
MX2021011596A (es) Compuestos y composiciones como moduladores de se?alizacion tlr.
TWD207993S (zh) 手錶
MX2023009921A (es) Formulaciones de proteinas de fusion ace2-fc.
CO2021011057A2 (es) Composición cosmética/dermatológica
CL2025000145A1 (es) Soluciones farmacéuticas de anticuerpos anti-n3pglu aß y usos de estas
MX2016005321A (es) Glicoproteinas recombinantes y sus usos.
WO2023081194A3 (fr) Méthodes de traitement de la maladie d'alzheimer
MX2022006674A (es) Composiciones de celulas t reguladoras (treg) y metodos para tratar enfermedades neurodegenerativas.
BR112021016795A8 (pt) Administração de inibidor de enzima de ativação de sumo e inibidores de checkpoint
BRPI0412506A (pt) células autólogas que induzem à autotoleráncia de origem monocìtica e seu uso em preparações farmacêuticos
BR112016007430A2 (pt) 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas
ECSP23082050A (es) Acetato de acetil sh-hexapéptido-5 amida para su uso en el tratamiento de trastornos de la caída del cabello y como agente para el cuidado del cabello